Psoriasis is a chronic immune-mediated condition that causes the skin to produce new cells at a rate dramatically faster than normal. Under healthy conditions, skin cells mature and shed over about a month. In psoriasis, this cycle compresses to three to four days — producing the characteristic thick, silvery-scaled plaques as immature cells accumulate faster than they can shed.
The most common form, plaque psoriasis, presents as raised, well-defined, red or salmon-colored patches covered with silvery white scale, most often on the elbows, knees, scalp, and lower back. Other clinical patterns — guttate (small drop-shaped lesions, often triggered by streptococcal infection), inverse (affecting skin folds), pustular, and erythrodermic — have distinct appearances and sometimes distinct management.
Approximately 30 percent of people with psoriasis develop psoriatic arthritis — an inflammatory joint disease that can cause significant joint damage if untreated. Patients with psoriasis are also at elevated risk for cardiovascular disease and metabolic syndrome. These aren’t minor comorbidities; they’re reasons to take psoriasis management seriously as a whole-health issue, not just a skin problem.
Treatment options by severity
Mild psoriasis is typically managed with topical therapies. Corticosteroids are the workhorse for acute flares. Vitamin D analogues (calcipotriene) used in combination with corticosteroids reduce steroid dependence and provide longer-term maintenance. Topical retinoids and calcineurin inhibitors have roles in specific locations. Scalp psoriasis has its own suite of options, including medicated shampoos and scalp solutions.
Phototherapy — Narrowband UVB specifically — is highly effective for moderate psoriasis, particularly when a large surface area is involved and topical treatment becomes impractical. It requires regular in-office sessions but avoids systemic medications. See the NBUVB Therapy page for details.
Moderate to severe psoriasis — defined by body surface area, involvement of functionally or cosmetically critical areas, or significant quality of life impact — is where the conversation about systemic treatment begins. Traditional systemic options include methotrexate and cyclosporine, both effective but requiring regular monitoring.
Biologics have transformed treatment for moderate to severe psoriasis over the past two decades. Targeted medications in the IL-17, IL-23, and TNF-alpha inhibitor classes produce skin clearance rates that were not achievable with prior treatments. Many patients on modern biologics achieve 90 percent or greater improvement in disease severity. They’re not without considerations — cost, injection requirements, and some immunosuppression — but for patients who have failed conventional therapy, they represent a genuine clinical advance.
Psoriatic arthritis
Patients with psoriasis should be screened regularly for joint symptoms — morning stiffness lasting more than 30 minutes, joint swelling, tendon or ligament inflammation (enthesitis), and nail changes associated with joint disease. Early identification and treatment prevents joint damage. When psoriatic arthritis is present, dermatology and rheumatology often manage the patient collaboratively.
Frequently asked questions
Will my psoriasis ever go away on its own?
Psoriasis is chronic. It can enter periods of remission — sometimes extended ones — but it typically returns. Guttate psoriasis triggered by streptococcal infection sometimes resolves after treatment of the infection, particularly in children and young adults.
Are biologics safe long-term?
The biologic class most commonly used for psoriasis has been in use for over 20 years with a generally reassuring long-term safety record. The main considerations are immunosuppression-related — increased susceptibility to certain infections. We review these risks specifically and help patients weigh them against the meaningful benefits of treatment for each individual situation.
I’ve only ever used a steroid cream. Are there other options worth trying?
Yes. Many patients with psoriasis have never been assessed for whether more targeted therapy is appropriate, or have been inadequately managed with topical-only treatment for conditions that would respond to phototherapy or systemic options. A current evaluation is often the first step toward meaningfully better control.